Internal medicine

Clinical endpoint

Lymphovascular invasion

Bladder cancer

Population

Cancer

Urology

Oncology

Cystectomy

Metastasis

Carcinoma in situ

Clinical trial

Medicine

Environmental health

The Lancet Oncology

Intravesical nadofaragene firadenovec was efficacious, with a favourable benefit:risk ratio, in patients with BCG-unresponsive non-muscle-invasive bladder cancer. This represents a novel treatment option in a therapeutically challenging disease state.

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial